TRPC3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL790364	0.77	17/20
SCHEMBL806596	0.74	17/20
SCHEMBL789250	0.70	17/20
SCHEMBL806707	0.60	17/20
SCHEMBL788993	0.68	16/20
SCHEMBL788988	0.59	16/20
SCHEMBL789564	1.00	13/20
SCHEMBL806654	0.75	13/20
SCHEMBL806650	0.56	13/20
SCHEMBL806925	0.77	12/20
SCHEMBL807011	0.58	12/20
SCHEMBL806645	0.58	12/20
SCHEMBL806600	1.00	11/20
SCHEMBL790396	0.77	11/20
SCHEMBL789038	0.77	11/20
SCHEMBL789898	0.75	11/20
SCHEMBL806599	0.58	11/20
SCHEMBL789503	1.00	10/20
SCHEMBL798463	1.00	10/20
SCHEMBL789873	0.81	10/20

Clinical trials — most relevant to TRPC3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls	PHASE4	COMPLETED
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients	PHASE2	COMPLETED
Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron	PHASE2	COMPLETED
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC	PHASE1	COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases	PHASE1	COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3	EARLY_PHASE1	COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.	nan	COMPLETED
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis	nan	UNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Dissecting the Heterogeneity of Oral Cancer Pain	nan	UNKNOWN
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin	nan	ENROLLING_BY_INVITATION
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy	nan	ENROLLING_BY_INVITATION
Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome	nan	COMPLETED
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy	nan	UNKNOWN
Visual Activity Evoked by Infrared in Humans After Dark Adaptation	nan	COMPLETED
A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin	nan	COMPLETED
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients	nan	ACTIVE_NOT_RECRUITING
Effect of FODMAPs on Mucosal Inflammation in IBS Patients	nan	UNKNOWN
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPC3 binder may also engage these)

Protein	Name	Similarity
Q9QZC1	—	0.997	Q9QZC1 →
Q9JMI9	—	0.993	Q9JMI9 →
TRPC7	Short transient receptor potential channel 7	0.991	landscape →
TRPC6	Short transient receptor potential channel 6	0.988	landscape →
Q9WVC5	—	0.988	Q9WVC5 →
Q61143	—	0.986	Q61143 →
Q9MYW0	—	0.983	Q9MYW0 →
Q91YD4	—	0.978	Q91YD4 →
E9PTA2	—	0.973	E9PTA2 →
TRPM2	Transient receptor potential cation channel subfamily M member 2	0.970	landscape →
Q32M45	—	0.963	Q32M45 →
Q5ZLG8	—	0.958	Q5ZLG8 →
Q8C5H1	—	0.958	Q8C5H1 →
Q6NXT6	—	0.958	Q6NXT6 →
Q9R283	—	0.957	Q9R283 →
A2BIE7	—	0.956	A2BIE7 →
Q4VBD2	—	0.955	Q4VBD2 →
Q9TU72	—	0.954	Q9TU72 →
Q5ZMP3	—	0.953	Q5ZMP3 →
Q9QZ71	—	0.953	Q9QZ71 →
Q9H2Y9	—	0.953	Q9H2Y9 →
A6QLE6	—	0.951	A6QLE6 →
Q9R244	—	0.951	Q9R244 →
Q4V8I4	—	0.951	Q4V8I4 →
Q9UBH6	—	0.950	Q9UBH6 →
Q80YA3	—	0.950	Q80YA3 →
Q5EAY8	—	0.949	Q5EAY8 →
Q9ULQ1	—	0.949	Q9ULQ1 →
Q9QZ70	—	0.949	Q9QZ70 →
MCOLN3	Mucolipin-3	0.948	landscape →